Junshi Biosciences Announces Approval of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Resectable NSCLC Patients

2 years ago

SHANGHAI, China, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a…

Apogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

2 years ago

SAN FRANCISCO and WALTHAM, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company…

Altimmune Announces Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 6, 2024

2 years ago

GAITHERSBURG, Md., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced an abstract…

XOMA Announces Stock Repurchase Program of up to $50 Million

2 years ago

Balanced capital allocation strategy looks to return capital to shareholders while continuing to invest in royalty and milestone acquisitions that…

Streamline Health® Expands Agreement With Existing eValuator™ Client to Add RevID™

2 years ago

6 facility New York health system becomes first client leveraging both eValuator and RevID to improve revenue integrity pre-bill Atlanta,…

Branded Legacy, Inc. ($BLEG) Retires Additional 442 Million Common Shares, Surpassing Initial Commitment

2 years ago

MELBOURNE, Fla., Jan. 02, 2024 (GLOBE NEWSWIRE) -- via IBN — Branded Legacy (OTC: BLEG) is further highlighting its commitment…

Theratechnologies Submits sBLA for Trogarzo® Intramuscular (IM) Method of Administration to FDA

2 years ago

Trogarzo® IM maintenance dosing aims to further enhance the convenience of non-oral therapy for heavily treatment-experienced adults with HIV Submission…

Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID

2 years ago

ATLANTA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on developing…

ExCellThera to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare Conference and to Participate in Upcoming Investor Conferences

2 years ago

MONTREAL, Jan. 02, 2024 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a world leader in blood stem cell therapies, announced today…

Apellis Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

2 years ago

WALTHAM, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at…